April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
The Expression of Growth Hormone Receptor in Uveal Melanomas
Author Affiliations & Notes
  • F. Buffe
    Ophthalmology and Pathology,
    UFCSPA, Porto Alegre, Brazil
  • Z. M. Correa
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • C. O. Degrazia
    UFCSPA, Porto Alegre, Brazil
  • L. M. Barbosa Coutinho
    UFCSPA, Porto Alegre, Brazil
  • Footnotes
    Commercial Relationships  F. Buffe, None; Z.M. Correa, None; C.O. Degrazia, None; L.M. Barbosa Coutinho, None.
  • Footnotes
    Support  ZMC-Unrestricted Grant from RPB, Inc.,New York, NY, and UC's Dept of Ophthalmology's privately supported Quest for Vision Fund
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 858. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Buffe, Z. M. Correa, C. O. Degrazia, L. M. Barbosa Coutinho; The Expression of Growth Hormone Receptor in Uveal Melanomas. Invest. Ophthalmol. Vis. Sci. 2010;51(13):858.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report the expression of growth hormone receptors (GHR) in uveal melanoma specimens.

Methods: : Retrospective review of paraffin embedded specimens of patients with uveal melanoma treated by enucleation at 2 institutions between 2002 and 2007. Specimens were stained initially with H&E to confirm the histopathologic diagnosis, cell type, and features such as vascular patterns, retinal and scleral invasion, and extra-ocular extension. Additional information regarding patient age, duration of follow-up, and detection of metastasis were computed. Non-stained sections were tested with immunohistochemical stain MAb 263, (Santa Cruz Biotechnology, Santa Cruz, CA, USA,) to determine the presence of GHR in tumor cells. All microslides (H&E and immuno) were reviewed by 2 independent blinded investigators and graded by each as positive or negative for MAb 263. Discrepant results were discussed and outside review was used to resolve discordant cases.

Results: : Forty-three paraffin embedded specimens were studied. Tumors were classified according to cell type into spindle B (n=15), mixed (n=15), epithelioid (n=12) and necrotic (n=1) cell types. The mean follow-up was 37.5 months. Through available follow-up, 72.1% of the patients were alive. Metastasis was detected in 18 patients (41.9%). Scleral and retinal invasion were observed in 44.2% and 51.2% of cases, respectively. Extraocular extension was identified in 18.6%. Thirty-eight of the 43 specimens (88.3%) exhibited positive immunoreactivity to MAb 263; among these, 19 were categorized as weakly positive, and the other 19 were categorized as strongly positive. Four cases were considered negative and one was excluded because was associated with a trend (P = 0.057) suggesting that tumors with positive immunoexpression might be associated with poorer prognosis.

Conclusions: : Growth hormone receptors were expressed by the majority of uveal melanoma specimens evaluated in this study MAb 236 posivitity may be prognostic of poor survival prognosis in uveal melanoma patients.

Keywords: melanoma • growth factors/growth factor receptors • immunohistochemistry 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.